suramin and Glioma
suramin has been researched along with Glioma in 27 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas." | 9.09 | Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ( Fisher, J; Grochow, LB; Grossman, SA; Lesser, G; Phuphanich, S; Piantadosi, S; Rozental, J, 2001) |
| " The aim of the study was to investigate the effect of suramin on the telomerase activity of C6 glioma cells and on the growth of C6 glioma spheroids." | 7.74 | The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells. ( Akev, N; Bilir, A; Erguven, M; Karabulut, E; Ozdemir, A, 2008) |
| "We have recently shown that glioma cell lines, as well as cells of human malignant gliomas in situ, synthesize tropoelastin." | 7.70 | Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells. ( Hinek, A; Jung, S; Rutka, JT, 1999) |
| "In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined." | 7.70 | Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. ( Bakker, JH; Bernsen, HJ; Boerman, RH; Peters, JP; Rijken, PF; van der Kogel, AJ; Wesseling, P, 1999) |
| "The antiestrogen tamoxifen is commonly used to treat breast cancer, but it also has therapeutic activity in several other types of cancer." | 7.70 | Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. ( Couldwell, WT; Lin, JH; Nedergaard, M; Song, H; Takano, T; Zhang, W, 2000) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 5.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 5.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| "To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas." | 5.09 | Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ( Fisher, J; Grochow, LB; Grossman, SA; Lesser, G; Phuphanich, S; Piantadosi, S; Rozental, J, 2001) |
| " The aim of the study was to investigate the effect of suramin on the telomerase activity of C6 glioma cells and on the growth of C6 glioma spheroids." | 3.74 | The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells. ( Akev, N; Bilir, A; Erguven, M; Karabulut, E; Ozdemir, A, 2008) |
| "We have recently shown that glioma cell lines, as well as cells of human malignant gliomas in situ, synthesize tropoelastin." | 3.70 | Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells. ( Hinek, A; Jung, S; Rutka, JT, 1999) |
| "In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined." | 3.70 | Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. ( Bakker, JH; Bernsen, HJ; Boerman, RH; Peters, JP; Rijken, PF; van der Kogel, AJ; Wesseling, P, 1999) |
| "The antiestrogen tamoxifen is commonly used to treat breast cancer, but it also has therapeutic activity in several other types of cancer." | 3.70 | Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. ( Couldwell, WT; Lin, JH; Nedergaard, M; Song, H; Takano, T; Zhang, W, 2000) |
| "The mechanism by which cyclic GMP synthesis is activated through a nucleotide receptor was studied in mouse neuroblastoma x rat glioma hybrid cells [108CC15 (NG 108-15)]." | 3.69 | Ca(2+)- and nitric oxide-dependent stimulation of cyclic GMP synthesis in neuronal cell line induced by P2-purinergic/pyrimidinergic receptor. ( Reiser, G, 1995) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 1.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 1.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| "Suramin is a competitive antagonist for the nucleotide receptor; reactive blue and DIDS are more selective antagonists for the P2Y receptor." | 1.29 | Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells. ( Chuang, DM; Lin, WW, 1994) |
| "Suramin treatment induced a 2-fold increase in immunoreactive FGFR and a 1." | 1.29 | Basic fibroblast growth factor binding and processing by human glioma cells. ( Knee, RS; Murphy, PR, 1995) |
| "Suramin is an anti-helminthic drug that has been shown to antagonize the effects of a variety of growth factors including EGF, PDGF and TGF beta." | 1.28 | [Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6]. ( Baghdiguian, S; Fantini, J; Marvaldi, J; Pichon, J, 1991) |
| "Suramin is a polyanionic compound currently used under evaluation for antineoplastic activity." | 1.28 | Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity. ( Baghdiguian, S; Fantini, J; Nickel, P, 1991) |
Research
Studies (27)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (77.78) | 18.2507 |
| 2000's | 6 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Erguven, M | 1 |
| Akev, N | 1 |
| Ozdemir, A | 1 |
| Karabulut, E | 1 |
| Bilir, A | 1 |
| Bellinzona, M | 1 |
| Roser, F | 1 |
| Matthies, C | 1 |
| Samii, M | 1 |
| Saini, M | 1 |
| Takano, S | 2 |
| Coomber, BL | 1 |
| Gately, S | 1 |
| Engelhard, H | 1 |
| Tsanaclis, AM | 1 |
| Brem, S | 1 |
| Reiser, G | 1 |
| Boyer, JL | 1 |
| Zohn, IE | 1 |
| Jacobson, KA | 1 |
| Harden, TK | 1 |
| Lin, WW | 2 |
| Chuang, DM | 1 |
| Westphal, M | 2 |
| Hamel, W | 1 |
| Zirkel, D | 1 |
| Herrmann, HD | 2 |
| Bilzer, T | 1 |
| Reifenberger, G | 1 |
| Schober, R | 1 |
| Wechsler, W | 1 |
| Albert, FK | 1 |
| Behnke, J | 1 |
| Chen, ZP | 1 |
| Krull, N | 1 |
| Xu, S | 1 |
| Levy, A | 1 |
| Lightman, SL | 1 |
| Murphy, PR | 1 |
| Knee, RS | 1 |
| Chen, BC | 1 |
| Lee, CM | 1 |
| Johnson, JP | 1 |
| Bruce, JN | 1 |
| Nagai, G | 1 |
| Nakaoka, Y | 1 |
| Badache, A | 1 |
| Muja, N | 1 |
| De Vries, GH | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Reyes, S | 1 |
| Ortiz, A | 1 |
| Rembao, D | 1 |
| Sotelo, J | 1 |
| Hinek, A | 1 |
| Jung, S | 1 |
| Rutka, JT | 1 |
| Bernsen, HJ | 1 |
| Rijken, PF | 1 |
| Peters, JP | 1 |
| Bakker, JH | 1 |
| Boerman, RH | 1 |
| Wesseling, P | 1 |
| van der Kogel, AJ | 1 |
| Zhang, W | 1 |
| Couldwell, WT | 1 |
| Song, H | 1 |
| Takano, T | 1 |
| Lin, JH | 1 |
| Nedergaard, M | 1 |
| Grossman, SA | 1 |
| Phuphanich, S | 1 |
| Lesser, G | 1 |
| Rozental, J | 1 |
| Grochow, LB | 1 |
| Fisher, J | 1 |
| Piantadosi, S | 1 |
| Meyer, RG | 1 |
| Küpper, JH | 1 |
| Kandolf, R | 1 |
| Rodemann, HP | 1 |
| Ackermann, E | 1 |
| Hoppe, J | 1 |
| Baghdiguian, S | 2 |
| Pichon, J | 1 |
| Marvaldi, J | 3 |
| Fantini, J | 4 |
| Nickel, P | 1 |
| Guo, XJ | 2 |
| Rougon, G | 2 |
| Roubin, R | 1 |
| Kuratsu, J | 1 |
| Ushio, Y | 1 |
Reviews
2 reviews available for suramin and Glioma
| Article | Year |
|---|---|
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
Angiogenesis in human gliomas: prognostic and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cyclohexanes; Endothelial Growth Factors; Epidermal | 1997 |
Trials
2 trials available for suramin and Glioma
| Article | Year |
|---|---|
Epidermal growth factor receptor expression in human malignant glioma: in vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Brain Neoplasms; Cell Division; Epidermal Growth Facto | 1994 |
Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Female; Glioma; Humans; Male; | 2001 |
Other Studies
23 other studies available for suramin and Glioma
| Article | Year |
|---|---|
The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells.
Topics: Animals; Bromodeoxyuridine; Cell Cycle; Cell Nucleolus; Cell Proliferation; DNA, Neoplasm; Glioma; R | 2008 |
Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours.
Topics: Animals; Antineoplastic Agents; Biopolymers; Brain Neoplasms; Drug Implants; Drug Screening Assays, | 2004 |
Suramin inhibits C6 glioma-induced angiogenesis in vitro.
Topics: Analysis of Variance; Animals; Cattle; Cell Division; Chemotaxis; Culture Media, Conditioned; Cultur | 1995 |
Suramin inhibits glioma cell proliferation in vitro and in the brain.
Topics: Animals; Brain Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, An | 1994 |
Ca(2+)- and nitric oxide-dependent stimulation of cyclic GMP synthesis in neuronal cell line induced by P2-purinergic/pyrimidinergic receptor.
Topics: Adenosine Triphosphate; Aminoquinolines; Animals; Bradykinin; Calcium; Colforsin; Cyclic GMP; Glioma | 1995 |
Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Cells, Cultured; Erythrocyte Membrane; Glio | 1994 |
Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells.
Topics: Adenylate Cyclase Toxin; Animals; Cyclic AMP; Glioma; Nucleotides; Pertussis Toxin; Phosphatidylinos | 1994 |
Molecular cloning and functional characterization of a rat pituitary G protein-coupled adenosine triphosphate (ATP) receptor.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Base Sequence; Blotting, Southern; Calcium; Cl | 1996 |
Basic fibroblast growth factor binding and processing by human glioma cells.
Topics: Animals; Base Sequence; Binding Sites; Cattle; Cross-Linking Reagents; DNA Primers; Fibroblast Growt | 1995 |
Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.
Topics: Adenosine Triphosphatases; Animals; Brain Neoplasms; Cell Line; Endothelium, Vascular; Enzyme Inhibi | 1996 |
Cooling sensitive [Ca2+]i response associated with signaling of G protein-coupled receptors.
Topics: Adenosine Triphosphate; Aniline Compounds; Animals; Calcium; Calcium-Transporting ATPases; Cold Temp | 1998 |
Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis.
Topics: Animals; Cell Division; Glioma; Humans; Hyperplasia; Neurilemmoma; Neurofibromatosis 1; Neurofibromi | 1998 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Cell surface aggregation of elastin receptor molecules caused by suramin amplified signals leading to proliferation of human glioma cells.
Topics: Cell Division; Culture Media, Serum-Free; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relations | 1999 |
Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Brain Neoplasms; Glioma; Humans; Hypoxia; Mice; Mice, | 1999 |
Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells.
Topics: Adenosine Triphosphate; Adult; Animals; Antineoplastic Agents, Hormonal; Astrocytes; Breast Neoplasm | 2000 |
Early growth response-1 gene (Egr-1) promoter induction by ionizing radiation in U87 malignant glioma cells in vitro.
Topics: Androstadienes; Anisomycin; Blotting, Western; Colforsin; DNA-Binding Proteins; Early Growth Respons | 2002 |
Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation.
Topics: Brain Neoplasms; Cell Division; Cell Line; Glioma; Humans; Neoplasm Proteins; Platelet-Derived Growt | 1991 |
[Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6].
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Col | 1991 |
Double screening of suramin derivatives on human colon cancer cells and on neural cells provides new therapeutic agents with reduced toxicity.
Topics: Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Drug Screening As | 1991 |
Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression.
Topics: Actins; Animals; Cell Adhesion Molecules; Cell Division; Dose-Response Relationship, Drug; Drug Eval | 1990 |
Evaluation of the effect of suramin on neural cell growth and N-CAM expression.
Topics: Animals; Brain; Cell Adhesion Molecules, Neuronal; Cell Division; Cell Line; Cells, Cultured; Embryo | 1990 |
Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro.
Topics: Animals; Glioma; Nimustine; Platelet-Derived Growth Factor; Pyrimidines; Suramin; Time Factors; Trap | 1990 |